These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 1800379)
1. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Knothe H; Shah PM; Eckardt O Infection; 1991; 19(5):370-6. PubMed ID: 1800379 [TBL] [Abstract][Full Text] [Related]
2. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Bauernfeind A; Jungwirth R Infection; 1991; 19(5):353-62. PubMed ID: 1800377 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Chin NX; Neu HC Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035 [TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218. Johnson DM; Jones RN Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735 [TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. Bauernfeind A Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin. Nishino T; Otsuki M; Hatano K; Nishihara Y Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity and cross resistance studies with cefpodoxime. Grimm H Zentralbl Bakteriol; 1991 Dec; 276(1):54-62. PubMed ID: 1789901 [TBL] [Abstract][Full Text] [Related]
10. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683 [TBL] [Abstract][Full Text] [Related]
11. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Knapp CC; Sierra-Madero J; Washington JA Antimicrob Agents Chemother; 1988 Dec; 32(12):1896-8. PubMed ID: 3245701 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers. Wiedemann B; Luhmer E; Zühlsdorf MT Infection; 1991; 19(5):363-9. PubMed ID: 1800378 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients. Sultan T; Baltch AL; Smith RP; Ritz W Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Neu HC Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B. Yu KW; Chin NX; Neu HC Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):652-9. PubMed ID: 1396779 [TBL] [Abstract][Full Text] [Related]
16. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001]. Abe T; Fukuoka T; Sato Y; Ito K; Sei M Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736 [TBL] [Abstract][Full Text] [Related]
17. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance. Cullmann W; Dick W; Stieglitz M; Opferkuch W Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045 [TBL] [Abstract][Full Text] [Related]
18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
19. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics. Kayser FH Infection; 1994; 22(5):370-5. PubMed ID: 7843823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]